Emcure Pharmaceuticals Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 27 Jun 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹37.2K Cr
Emcure projects low to mid-teen revenue growth for FY27, driven by diversified business verticals and geographies including domestic, Canada, Europe, and Emerging markets. Emcure expects low to mid-teen revenue growth in FY27 and beyond.
From Emcure Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,863
Market Cap
₹37.2K Cr
P/E Ratio
39.3
How does Emcure Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Emcure Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Emcure Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹2.5K Cr, net profit ₹244 Cr.
Full financials →📊 Revenue & Sales Performance
- →Emcure projects low to mid-teen revenue growth for FY27, driven by diversified business verticals and geographies including domestic, Canada, Europe, and Emerging markets.
- →Domestic market expected to grow faster than industry (~8-9%) at low double-digits, supported by strong teams and portfolios in cardio-diabetes, biologics, women's health, and new initiatives.
- →International markets (Europe, Canada, Emerging markets) expected to maintain strong growth, with Europe's business projected for mid-teens CAGR over the next 2 years. Amphotericin B launch is a key growth driver.
- →Growth levers include ramp-up of semaglutide partnership, dermal product Emcutix, consumer business Arth, and new launches.
- →Biosimilar market expected to heat up due to lowered FDA R&D requirements; Emcure’s experience positions it well to thrive.
- →Focus on execution, processes, people, and optimized margins will support sustained above-industry growth and margin expansion by 75-100 basis points annually.
📈 Profitability & Margins
- →Emcure expects low to mid-teen revenue growth in FY27 and beyond.
- →EBITDA margins are projected to expand by 75 to 100 basis points annually, driven by operating leverage and productivity gains.
- →Adjusted PAT grew over 40% in FY26, indicating strong profit growth traction.
- →Continued margin expansion is anticipated through scale benefits and synergy realization.
- →Growth drivers include domestic market strength (especially Cardio-Diabetes, biologics, women's health), semaglutide partnership, Emcutix derma product, consumer health segment, and international markets (Canada, Europe, Emerging Markets).
- →Amphotericin B launch and biosimilars (like Bevacizumab) are expected to contribute to near-term profitability.
- →Emcure aims for sustainable above-industry growth with margin improvement and long-term value creation.
- →Management is confident of execution delivering results consistent with market expectations going forward.
🏗️ Capital Expenditure Plans
- →For FY27, Emcure Pharmaceuticals plans a capital expenditure (capex) of approximately INR 400-425 crores.
- →The company continues to invest in R&D, with FY26 R&D investments at INR 383.5 crores (4.2% of revenue), supporting pipeline development in complex injectables, biosimilars, novel delivery routes, and Antibody Drug Conjugates (ADC).
- →Strategic investments include in-licensing deals (e.g., partnership with Novo Nordisk for Poviztra, expanded partnership with Sanofi for Amaryl & Cetapin, and distribution agreement with Roche for nephrology drugs).
- →Mergers and acquisitions highlight consolidation in the UK (Manx portfolio), Canada (Cutimed derma range), and full consolidation of Zuventus business in India.
- →Future growth will focus on execution, people, process improvements, and geographic diversification (India, Canada, Europe, Emerging Markets).
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
- →Emcure's non-ARV business, which is crucial for revenue diversification, maintains a strong order book.
- →The HIV segment continues to enjoy a pole position with a robust ARV order book.
- →The company has ongoing registrations in various markets supporting this strong order book.
- →Emcure filed the DMF for Gilead Lenacapavir and expects product registration in FY27, indicating pending orders in the pipeline.
- →Overall, international markets show sustained growth driven by a robust order book in ARV and non-ARV segments.
Key Metrics
Frequently Asked Questions
What were Emcure Pharmaceuticals Ltd Q4 FY26 results?
Emcure projects low to mid-teen revenue growth for FY27, driven by diversified business verticals and geographies including domestic, Canada, Europe, and Emerging markets. Emcure expects low to mid-teen revenue growth in FY27 and beyond.
What is Emcure Pharmaceuticals Ltd share price analysis?
Emcure Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 39.3 with a market cap of ₹37,158 Cr. Investors should review the full earnings analysis for detailed insights.
Is Emcure Pharmaceuticals Ltd planning capital expenditure?
For FY27, Emcure Pharmaceuticals plans a capital expenditure (capex) of approximately INR 400-425 crores.
Keep Emcure Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.